Table 1.

Distribution of first biologic DMARDs in RA patients according to 5-years periods

2001-20052006-20102011-20152016-2020Total
Adalimumab15 (23.1)111 (33.0)187 (21.8)153 (18.6)466 (22.4)
Etanercept30 (46.2)154 (45.8)229 (26.7)54 (6.6)467 (22.4)
─░nfliximab20 (30.8)58 (17.3)64 (7.5)7 (0.9)149 (7.1)
Golimumab0037 (4.3)43 (5.2)80 (3.8)
Certolizumab0037 (4.3)68 (8.3)105 (5.0)
Anti-TNF65 (100)323 (96.4)554 (64.5)325 (39.5)1267 (60.9)
Tofacitinib006 (0.7)212 (25.8)218 (10.5)
Tocilizumab009 (1.0)102 (12.4)111 (5.3)
Rituximab012 (3.6)136 (15.8)84 (10.2)232 (11.1)
Abatacept00153 (17.8)99 (12.0)252 (12.1)
Non-Anti-TNF012 (3.6)304 (35.5)497 (60.5)813 (39.1)
Total65 (100)335 (100)858 (100)822 (100)2080 (100)
  • Approval years of drugs in Turkey; Infliximab: 2003, etanercept:2004, adalimumab: 2005, golimumab: 2013, certolizumab: 2014, abatacept: 2010, tocilizumab: 2013, rituximab:2009, tofacitinib: 2015,